AbbVie R&D has expanded its synthetic capabilities to include organic electrochemistry in active pharmaceutical ingredient (API) and metabolite synthesis. Elimination of hazardous reagents and waste is an important benefit in addition to the technology’s versatility and selectivity. Recent advancements made by AbbVie and collaborative academic chemists are discussed herein.